Fellowship · Los Angeles, CA
Sponsored by UCLA David Geffen School of Medicine/UCLA Medical Center
Psoriasis.
Lancet (London, England) · 2021 · 1,948 citations · April Armstrong
Psoriasis.
Nature reviews. Disease primers · 2025 · 152 citations · April Armstrong
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Journal of the American Academy of Dermatology · 2023 · 292 citations · April Armstrong
Psoriasis Prevalence in Adults in the United States.
JAMA dermatology · 2021 · 359 citations · April Armstrong
Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study.
The European respiratory journal · 2025 · 78 citations · April Armstrong
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
Journal of the American Academy of Dermatology · 2021 · 228 citations · April Armstrong
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
The New England journal of medicine · 2023 · 156 citations · Walter Nahm
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
JAMA dermatology · 2023 · 129 citations · April Armstrong